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Summary  
The fact that non-valvular (non-rheumatic) atrial fi-
brillation creates detectable thrombi in 17% of patients 
without oral anticoagulation and that 16% of the 17% 
(over 90% relatively) reside in the left atrial appendage 
(LAA), suggest that patients without an LAA or with 
an occluded LAA do not need oral anticoagulation. 
This has already led to surgical LAA exclusion for de-
cades and to catheter-based LAA occlusion for the past 
13 years. 
Currently 5 different technical approaches are ap-
proved in European countries, but only 2 are widely 
used, the Amplatzer and the Watchman devices. With 
the latter, randomised data showed superiority in 
terms of embolism protection, bleeding, and survival 
compared to vitamin K antagonists (VKA) after 4 years 
in a randomised trial. The clinical results in thousands 
of patients with Watchman and Amplatzer occluders 
suggest, moreover, that they are at least competitive 
with non-VKA oral anticoagulants. Non-pharmacolog-
ical prevention of thromboembolism with device im-
plantation or, in case of another indication for heart 
surgery during that intervention, may be discussed 
with every patient with atrial fibrillation as an alter-
native to oral anticoagulation. 
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Introduction
It is known from autopsy, cardiac surgery, and trans- 
oesophageal echocardiography (TOE) that 17% of pa-
tients with non-valvular (basically non-rheumatic) 
atrial fibrillation (AF) have clots in the left atrium 
(LA). Over 90% of these clots (16% 
of 17%) reside in the left atrial ap-
pendage (LAA) [1]. Hence, the pres-
ence of 1% of blood clots in patients 
with no LAA or an occluded LAA 
provides a risk much too small to 
warrant chronic oral anticoagula-
tion either with vitamin K antago-
nists (VKA) or non-VKA oral anti-
coagulants (NOAC). The bleeding risk more than out-
weighs the potential benefit. 
AF is the most common clinically significant 
rhythm disorder with an increasing prevalence paral-
lel to the increasing average age of our population. The 
decision of whether to treat a given patient with VKA, 
NOAC, or LAA occlusion has to be taken almost daily 
by cardiologists, internists, and other physicians. 
Techniques of left atrial appendage occlusion
Excision or ligation of the LAA has been part of some 
surgical procedures for decades [2, 3]. However, these 
interventions were mostly combined with mitral valve 
replacement using metallic implants so that the pa-
tients needed to stay under oral anticoagulation re-
gardless. No thorough appreciation of the value of LAA 
exclusion was therefore performed or even possible.
The electrophysiologist Michael Lesh developed a 
plug device that could be implanted percutaneously, in-
trigued by the fact that the LAA was easily accessible 
with catheters used for AF ablation in the LA. He at-
tended the first implantation of his Percutaneous Left 
Atrial Appendage Transcatheter Occluder (PLAATO, 
abandoned, Medtronic, Mansfield, MA, USA) on  August 
30, 2001, by Horst Sievert in Frankfurt, Germany [4]. 
The results of patients treated with this device were 
superior to what could be expected with VKA [5, 6]. The 
procedure itself, however, was rather intricate, partly 
due to bulky catheters.
On June 15, 2002, we introduced a more simple 
technique applicable in a conscious patient under local 
anaesthesia and without echocardiographic guidance. 
This technique used various Amplatzer devices 
(St. Jude, Plymouth, MS, USA) that were market lead-
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Most patients undergo a TOE before the procedure 
to rule out mobile clots in the LAA. It is possible to per-
form the procedure without prior TOE but this requires 
a contrast medium injection into the LA at a distance 
of the LAA to assess for thrombus [17]. While most 
 operators prefer a trans-septal puncture through the 
septum primum low and posterior in the fossa ovalis, a 
PFO and, even better, an ASD when present can be 
used for LA access in most cases. The LAA occlusion 
can be combined with a variety of other interventions, 
most commonly coronary angiography, yielding an as-
sociated procedure in 41%, 2 associated procedures in 
32%, 3 in 6%, and 4 or more in 1% at our centre (fig. 3). 
We finish the LAA occlusion with closing a pre-existing 
atrial septal passage using the same delivery sheath 
for a second Amplatzer (ASD or PFO) occluder. 
A specifically shaped sheath (13 French = 4.3 mm 
inner and 5.5 mm outer diameter) is gently introduced 
into the left atrial appendage and the device is im-
planted through it. This is performed under heparin 
(e.g., 5000 units before beginning the procedure) and 
antibiotic protection (e.g., 1 g of cephalosporin before 
the procedure and at least once after the procedure). 
Stable position of the device and absence of pericardial 
effusion is usually confirmed by transthoracic echo-
cardiography a few hours later (after mobilisation) and 
the patient is often discharged the same day. The latest 
moment of device embolisation appears to be the mobi-
lisation of the patient leading to markedly altered po-
sition of the heart. Either oral anticoagulation for a few 
weeks followed by acetylsalicylic acid (ASA) or, at our 
centre, clopidogrel for 1 month and ASA for 5 months 
with or without loading doses are used after discharge. 
We recommend a TOE at 3 to 6 months to assure 
proper closure of the LAA and absence of mobile 
thrombi or of thrombi protruding into the LA.
ers in the closure of atrial septal defects (ASD) and pat-
ent foramen ovale (PFO) [7]. Figure 1 shows the 1-year 
follow-up echocardiogram of the world’s first patient. 
Later the same year, the Watchman device (Boston 
Scientific, Marlborough, MA, USA) was introduced into 
clinical medicine (first case on August 12, 2002, per-
formed by Peter Sick) [8]. This device and the Am-
platzer devices, in particular the Amplatzer Cardiac 
Plug (ACP), a modification of the original Amplatzer 
devices introduced in 2008, currently dominate the 
market [9, 10]. The LAA Transcatheter Patch (Custom 
Medical Devices, Athens, Greece) and the WaveCrest 
device (Johnson and Johnson, Diamond Bar, CA, USA), 
the two other devices that are clinically used in  Europe, 
are depicted in figure 2. On rare occasions a hybrid pro-
cedure using a left atrial approach combined with a 
pericardial approach is used [11–13]. This technique is 
more in competition with mini-invasive surgery [14] 
than with interventional cardiology. 
Percutaneous technique for left atrial 
 appendage occlusion
While most centres prefer general anaesthesia with 
 endotracheal intubation and TOE guidance, simplifica-
tions have been suggested [15]. TOE guidance is possi-
ble with deep sedation but bronchial aspiration has to 
be watched out for (table 1). Intracardiac echocardiog-
raphy (ICE) has also been recommended [16]. Our 
group has had good experience with the most frugal of 
all approaches [10].
Table 1 
Advantages and disadvantages of echocardiographic guidance 
(trans-oesophageal or intracardiac) for left atrial appendage 
closure.
Advantages
Less misplacement or sub-optimal placement of device
Less misplacement of additional shunts
Immediate information about result
Less (no) contrast medium injection
Less (no) X-ray exposure
Disadvantages
Need for general anaesthesia or intubation 
or else: tube uncomfortable in supine position and risk 
of  bronchial aspiration
Cost and complications of intracardiac echocardiography 
(2nd venous access)
Distraction from what is essential in fluoroscopy
Much longer procedure (clots in sheath!)
Figure 1
Trans-oesophageal echocardiography of the world’s first patient with 
a left atrial appendage occlusion under non-sedated local anaesthesia 
and without echocardiographic guidance. The patient was a 63-year-
old butcher with atrial fibrillation. He could not take oral anticoagu-
lants for professional reasons. The procedure was performed on June 
15, 2002, using an Amplatzer 30 mm Atrial Septal Occluder and the 
patient has had no further need for anticoagulation in a clinically 
uneventful course for over 12 years.
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Complications of left atrial appendage occlusion
Device embolisation and cardiac perforation with peri-
cardial bleeding are the most feared complications and 
occur in about 1 to 3% each. They appear to be device-
independent and to occur less frequently with more 
 experienced operators. However, the technique is intri-
cate and the learning curve is rather flat. Late device 
embolisations that have been reported were probably 
misinterpreted early device embolisations that were 
clinically silent (as practically all device embolisations 
are) and were detected only late. Late pericardial effu-
sions, however, do occur, probably more due to pericar-
dial reactions than to late perforations. Nonetheless, 
late erosion for instance of a pulmonary artery by the 
retainer hook of an LAA occluder has been reported 
[18]. Late mobile thrombi on the device detected either 
by routine TOE follow-up or after a clinical event occur 
in 3 to 5%. They may need a period of VKA or NOAC if 
feasible for the patients. Thrombectomy, perhaps with 
surgical explantation of the device, is an alternative 
but has rarely been reported. 
Figure 2
Left atrial append-
age occluders used 
in Europe with their 
year of introduc-
tion. The Amplatzer 
devices are the 
most commonly 
used ones followed 
by the Watchman 
devices.
Figure 3
Procedures 
associated to left 
atrial appendage 
occlusion at our 
institution in 
413 cases. 
AF = atrial 
fibrillation; ASD = 
atrial septal defect; 
PCI = percutaneous 
coronary interven-
tion; PFO = patent 
foramen ovale; RF 
= radio frequency; 
TAVI = transcatheter 
aortic valve 
implantation.
Cardiovascular Medicine 2014;17(9):252–255 255
REVIEW ARTICLE
Clinical results of left atrial appendage occlusion
The results of 2 randomised trials with the Watchman 
device (PROTECT AF, and PREVAIL) [15] and registry 
publications of thousands of patients treated with 
Watchman or Amplatzer devices [19–21] attest reason-
able safety and surprising efficacy. In particular, the 
Watchman device proved to reduce mortality over 
4 years when compared to Warfarin treatment [20]. A 
large registry using the Amplatzer device with over 
1000 patients showed a mortality curve congruent with 
that of the PROTECT AF trial [21]. This suggests that 
both currently leading techniques may be not only 
superior to VKA but are probably also competitive with 
NOAC. A respective randomised trial with the Am-
platzer device is ongoing. 
A cost analysis projected that about 50 000 US dol-
lars have to be invested for 1 quality-adjusted year of 
life with LAA closure compared to VKA while this costs 
90 000 US dollars with dabigatran, the hitherto most 
widely used NOAC [22].
Conclusion
Clinical results with LAA occlusion confirm the theory 
that eliminating the LAA as a possible source of sys-
temic emboli in AF provides at least as good a protec-
tion against systemic emboli as oral anticoagulation 
with VKA and probably also with NOAC and yields a 
net benefit because the constant bleeding risk (growing 
with age) with any type of oral anticoagulation is virtu-
ally eliminated. Hence, this option may be discussed 
with every patient with atrial fibrillation irrespective 
of whether or not anti-thrombotic treatment has 
 already been started. This has yet to be reflected in 
guidelines where LAA closure is at best mentioned as 
an alternative for oral anticoagulation in patients with 
contraindications to it or unwilling to take it. Moreover, 
as both methods fail to provide complete prevention 
against systemic embolism, a combination of them can 
be considered.
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